Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28400562 | 0.79 | MAPT (0.33) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL15468118 | 0.71 | MAPT (0.36) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL8890839 | 0.70 | MAPT (0.35) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL3905504 | 0.69 | MAPT (0.34) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL897853 | 0.68 | CDC25B (0.38) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| Hydrochloric Acid SCHEMBL7484754 | 0.68 | MAPT (0.33) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| Hydrochloric Acid SCHEMBL7482838 | 0.68 | MAPT (0.33) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL9666118 | 0.67 | MAPT (0.38) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL29161382 | 0.66 | MAPT (0.54) | MAPTALDH1A1LMNAKMT2AMAPK10 | |
| SCHEMBL1820520 | 0.66 | ALDH1A1 (0.33) | MAPTALDH1A1LMNAKMT2AMAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181240-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9096591-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034880-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-05-19 | — | — | US | disclosed |
| US-8999978-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES INC. | 2013-08-08 | — | — | US | disclosed |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8338408-B2 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090239854-A1 | Tetracyclic compounds | MEDIVATION TECHNOLOGIES, INC. | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150182509-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
| US-20130131054-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
| US-20130203746-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
| US-20130190304-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
| US-20090239854-A1 | Tetracyclic compounds | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
| US-20140194414-A1 | TETRACYCLIC COMPOUNDS | HTR2C, HTR3D, HTR5A | MAPT 252/4885ALDH1A1 1557/4885LMNA 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.